The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
Epioxa by Glaukos Corp received US Food and Drug Administration (FDA) approval on 20 October as the first and only ...
Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...
As healthcare systems work towards new sustainability goals, medical textiles have become a key focus for innovation.
Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets.
Helex has raised $3.5m in a seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney ...
The FDA's draft guidance is supposed to cut the cost and time-associated burden of biosimilar development, despite a mixed ...
Eli Lilly will invest over $1.2bn into its manufacturing site in Puerto Rico, as it aims to assemble a robust supply chain ...
Health Canada has issued a Notice of Compliance (NOC) for AstraZeneca’s HER2-directed antibody drug conjugate (ADC) Enhertu.
While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.
Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results